2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
05/17/17Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder
Top Line Results Expected in 3Q 2017 GERMANTOWN, Md., May 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, today announced it has completed dosing of the last subject in its multicenter Phase 2 clinical trial evaluating the efficacy of NSI-189 for the treatment of major depressive disorder (MDD).  NSI-189 is an oral antidepressant with a novel mechanism of action and is the lead compound ... 
 Printer Friendly Version
05/10/17Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
Phase 2 MDD clinical trial results expected in 3Q17, Extended runway of cash into 3Q18 GERMANTOWN, Md., May 10, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, reported its financial results for the quarter ended March 31, 2017.             “This is an exciting time for the company as we approach a large clinical milestone of NSI-189 Phase 2 major depressive disorder (MDD) study results, ... 
 Printer Friendly Version
04/12/17Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury
Investigating New Patient Cohort with Cervical Injury GERMANTOWN, Md., April 12, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announced that a new cohort of four patients will be added to its ongoing Phase 1 human clinical trial evaluating the safety and feasibility of using NSI-566 spinal cord-derived neural stem cells to repair chronic spinal cord injury (c... 
 Printer Friendly Version
03/23/17Neuralstem Reports Year End 2016 Fiscal Results and Business Update
Expects to Report NSI-189 Phase 2 major depressive disorder study results in Q3 ahead of schedule GERMANTOWN, Md., March 23, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, reported its financial results for the fourth quarter and year ended December 31, 2016. “We are pleased with the execution over the past year that includes securing a strategic investment, b... 
 Printer Friendly Version
03/17/17Neuralstem to Present at Oppenheimer 27th Annual Healthcare Conference on March 21
GERMANTOWN, Md., March 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announces that Rich Daly, Chairman and CEO of Neuralstem, will present at the Oppenheimer 27th Annual Healthcare Conference at The Westin New York Grand Central in New York.  The presentation is scheduled for Tuesday, March 21, 2017 at 1:00 p.m. Eastern time. The live audio webcast of t... 
Download PDFPrinter Friendly Version
03/09/17Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury
-NSI-566 Achieved Robust Engraftment and Long-Term Survival After Transplantation- - Data Published in Journal of Neurotrauma- GERMANTOWN, Md., March 09, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announced the recent publication of preclinical data on NSI-566 spinal cord-derived neural stem cells in Journal of Neurotrauma.  These data showed robust engr... 
Download PDFPrinter Friendly Version
03/08/17Neuralstem to Present at 29th Annual ROTH Conference
GERMANTOWN, Md., March 08, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announces that Rich Daly, Chairman and CEO of Neuralstem, will present at the 29th Annual ROTH Conference at The Ritz-Carlton in Orange County, California.  The presentation is scheduled for Monday, March 13, 2017 at 12:00 p.m. Pacific time. To view the live audio webcast of the present... 
Download PDFPrinter Friendly Version
02/28/17Neuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology
-NSI-189 Showed Durable Functional Recovery in a Rodent Model of Ischemic Stroke- -NSI-189 Promoted Synaptic Remodeling After Stroke- GERMANTOWN, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announced the recent publication of preclinical data on NSI-189 in Journal of Cellular Physiology.  The study demonstrated that NSI-189 improved behavior... 
Download PDFPrinter Friendly Version
02/22/17Neuralstem Announces Issuance of U.S. Patent Covering NSI-189
GERMANTOWN, Md., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that U.S. Patent No. 9572807 was issued by the United States Patent and Trademark Office (USPTO) for NSI-189, the lead compound in Neuralstem's neurogenic small molecule program in development for the treatment of major depressive disorder. US 9,572,807 has claims to... 
Download PDFPrinter Friendly Version
02/16/17Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder
- Phase 2 Data Now Expected Ahead of Schedule in 3Q 2017 - GERMANTOWN, Md., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced completion of subject enrollment in its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder (MDD).  NSI-189 is a new chemical entity and the lead compound in Neuralstem's neuroge... 
Download PDFPrinter Friendly Version
02/13/17Neuralstem to Present at BIO CEO & Investor Conference
GERMANTOWN, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announces that Rich Daly, Chairman and CEO of Neuralstem, will present at the BIO CEO & Investor Conference at the Waldorf Astoria New York on Monday, February 13, 2017.  The presentation is scheduled at 8:30 am EST. To view the live audio webcast of the presentation please visit... 
Download PDFPrinter Friendly Version
01/06/17Neuralstem Announces a 1-for-13 Reverse Stock Split
GERMANTOWN, Md., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-13. The reverse stock split will become effective on Friday, January 6, 2017 after market close and shares of Neuralstem Inc. common stock will trade on a post-split basis on the Nasdaq Capital M... 
Download PDFPrinter Friendly Version